51028-73-0

Basic information

• Product Name: 4-[(1R)-1-hydroxy-2-methylamino-ethyl]benzene-1,2-diol
• Synonyms: (R)-Adrenaline;1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, (theta)-;1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
• CAS NO: 51028-73-0
• Molecular Formula: C9H13NO3
• Molecular Weight: 0
• Mol File: 51028-73-0.mol
• Article Data: 25

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-[(1R)-1-hydroxy-2-methylamino-ethyl]benzene-1,2-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(1R)-1-hydroxy-2-methylamino-ethyl]benzene-1,2-diol(51028-73-0)
• EPA Substance Registry System: 4-[(1R)-1-hydroxy-2-methylamino-ethyl]benzene-1,2-diol(51028-73-0)

Safety Data

• Hazardous Substances Data: 51028-73-0(Hazardous Substances Data)

Upstream product

• 99-45-6 adrenalone 
• 51-43-4 (-)-epinephrine 
• 36467-25-1 2-(benzyl-methyl-amino)-1-(3,4-dihydroxy-phenyl)-ethanone 
• 59-42-7 L-(-)-phenylephrine 
• 329-65-7 Epinephrine 
• 104819-56-9 S-(-)-2,2'-dinitrobiphenyl-6,6'-dicarbonsaeure-di-N,N'-1-(3,4-dihydroxyphenyl)-1-oxo-2-methylamido-ethan 
• 87-69-4 L-Tartaric acid 
• 104819-58-1 S-(-)-2,2'-dinitrobiphenyl-6,6'-dicarbonsaeure-di-N,N'-1-(3,4-dihydroxyphenyl)-1-hydroxy-2-methylamido-ethan 
• 62-13-5 1-(3,4-dihydroxyphenyl)-1-oxo-2-methylamino-ethan-hydrochlorid 
• 101878-49-3 benzyl (2-(3,4-dihydroxyphenyl)-2-oxoethyl)(methyl)carbamate 
• 16536-89-3 (R)-4-(1-hydroxy-2-(methylamino)ethyl)benzen-1,2-diol L-tartrate 
• 120-80-9 benzene-1,2-diol 
• 59-92-7 levodopa 
• 60-18-4 L-tyrosine 

Downstream Products

• 26405-77-6 (+/-)-epinine β-sulfonate < (+/-)-N-methyl-2-(3,4-dihydroxyphenyl)ethylammonium-2-sulfonate > 
• 103565-58-8 (R)-2-(acetyl-methyl-amino)-1-(3,4-dihydroxy-phenyl)-ethanol 
• 115780-42-2 C₉H₁₂NO₃ 
• 99-45-6 adrenalone 
• 51-43-4 L-epinephrine 
• 150-05-0 (S)-4-[1-hydroxy-2-(methylamino)ethyl]pyrocatechol 
• 1095097-66-7 4-(4-aminophenylazo)naphthalen-1-amine 

Relevant articles and documents

In-situ and one-step preparation of protein film in capillary column for open tubular capillary electrochromatography enantioseparation

In this work, the phase-transitioned BSA (PTB) film using the mild and fast fabrication process adhered to the capillary inner wall uniformly, and the fabricated PTB film-coated capillary column was applied to realize open tubular capillary electrochromatography (OT-CEC) enantioseparation. The enantioseparation ability of PTB film-coated capillary was evaluated with eight pairs of chiral analytes including drugs and neurotransmitters, all achieving good resolution and symmetrical peak shape. For three consecutive runs, the relative standard deviations (RSD) of migration time for intra-day, inter-day, and column-to-column repeatability were in the range of 0.3%–3.5%, 0.2%–4.9% and 2.1%–7.7%, respectively. Moreover, the PTB film-coated capillary column ran continuously over 300 times with high separation efficiency. Therefore, the coating method based on BSA self-assembly supramolecular film can be extended to the preparation of other proteinaceous capillary columns.

Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target

Finasteride, a 5-alpha reductase (5α-R) inhibitor, is a widely used drug for treating androgen-dependent conditions. However, its use is associated with sexual, psychological, and physical complaints, suggesting that other mechanisms, in addition to 5α-R inhibition, may be involved. Here, a multidisciplinary approach has been used to identify potential finasteride off-target proteins. SPILLO-PBSS software suggests an additional inhibitory activity of finasteride on phenylethanolamine N-methyltransferase (PNMT), the limiting enzyme in formation of the stress hormone epinephrine. The interaction of finasteride with PNMT was supported by docking and molecular dynamics analysis and by in vitro assay, confirming the inhibitory nature of the binding. Finally, this inhibition was also confirmed in an in vivo rat model. Literature data indicate that PNMT activity perturbation may be correlated with sexual and psychological side effects. Therefore, results here obtained suggest that the binding of finasteride to PNMT might have a role in producing the side effects exerted by finasteride treatment.

PROCESS FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS

Subject-matter of the present invention is a process for the preparation of optically active phenyl-beta-amino alcohols by means of a specific reduction of the corresponding phenyl-beta-amino ketones. Further subject-matter of the invention are said novel synthesis intermediates and their use for the preparation of active pharmaceutical ingredients.